Wellthy Therapeutics was one of G4A’s 2019 Growth Track finalists. The company o!ers a digital therapeutics platform for chronic disease management across multiple therapeutic areas including type II diabetes, hypertension, dyslipidemia, congestive heart failure, ischemic heart disease, clinical obesity, chronic kidney disease, asthma, pulmonary arterial hypertension, and others.
Since its inception in 2016, the company has raised a total of $8.5 million and has achieved a $25 million post-valuation, the highest out of G4A’s Growth Track finalists to date. As of 2020, Wellthy has presence in 636+ cities and stands at 20+ clinical publications recognized globally. The company’s mission is to enable 10 million patients to reverse, prevent or control their chronic condition by 2030.
Wellthy Therapeutics is one of the many companies that have benefited from G4A’s digital health acceleration program. Abhishek Shah, Wellthy’s CEO, describes the program as the most fun, well-structured, and informative accelerator they have been a part of and highlights how the insights they gained from the coaching sessions really broadened their capabilities.
(G4A is) the most
Wellthy Therapeutics CEO